



FACILITY OVERVIEW

Leiden, Netherlands

Charles River's discovery-focused site in Leiden uses a combination of functional genomics technologies coupled with screening in human (primary) cells to identify and validate critical proteins in disease pathways. The team has in-depth expertise both in developing and performing disease-relevant assays and in setting up complex, high quality screens.

Background

- Founded in 1999 as BioFocus, a clinical-stage biotechnology company that was acquired by Galapagos, NV in 2005
- BioFocus was acquired by Charles River in 2014 to complete the unique integrated drug discovery service offering, from target identification to delivery of a clinical candidate

Laboratories and Facilities

- Located in the Leiden Bio Science Park, the largest life science cluster in Netherlands
- 1,764 square meters/18,988 square feet
- Biosafety Levels (BSL) 1 and 2

Staff

- Approximately 75 scientific staff members
- 35% PhDs, 65% MSc and BS degrees

Service Areas/Study Types

- Target discovery and validation
 - Proprietary adenoviral shRNA (SilenceSelect®) and cDNA (FlexSelect®) libraries targeting the druggable human genome
 - CRISPR/Cas9 technology
 - Human (primary) cell-based assay development
 - High-throughput phenotypic screening
 - Mode of action studies
- Cell biology
- Human and primary stem cells

- Access to patient-derived (PD) tissues and clinical networks
- High content analysis
- Disease area experiences include rheumatoid arthritis, cancer, metabolism, osteoarthritis, osteoporosis, obesity, Alzheimer's disease, Huntington's disease, atherosclerosis, allergic rhinitis and others

Compliance, Certifications, Accreditations and Professional Affiliations

Charles River's Leiden facility operates in compliance with the requirements of the following regulatory agencies or accredited organizations:

- ISO 9001 certification
- GMO certified (BSL 1 and 2)
- CIR accreditation



EVERY STEP OF THE WAY